Topic: Non-Muscle Invasive Bladder Cancer

Controversies in Non-Muscle Invasive Bladder Cancer

Siamak Daneshmand, MD, reports on recent controversies in treatment for non-muscle invasive bladder cancer (NMIBC) regarding chemotherapy options for reducing post-transurethral resection (TUR) recurrences and active surveillance for low-grade patients, as well as alternatives to cystectomy in high-grade patients.

Read More

En Bloc TURB – More Than a Safe and Feasible Surgical Technique

Salvatore Micali, MD, discusses the pros and cons of en bloc transurethral resection of bladder (TURB) and its advantages over classical TURB. Specifically, he describes how en bloc TURB lends itself to correct specimen orientation, easier identification of the tumor growth front and whether the disease has invaded the chorion, and better determination of the deep surgical margin.

Read More

Should Variant Histology Change Management of Bladder Cancer?

Peter Black, MD, FRCSC, fills in for Ashish Kamat, MD, at the 2nd annual IBCU, discussing why and how clinicians should adapt bladder cancer treatment based on variant histologies. Dr. Black identifies sub-types of bladder cancer and the way gene expression and squamous differentiation play a role in risk-stratifying the disease. He explains the proper management of each sub-type, including MD Anderson treatment algorithms for NMIBC and MIBC.

Read More

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guidelines

Sam Chang, MD, MBA, who has served as chair of the American Urological Association (AUA) guidelines panel for non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC), provides an overview of updated non-metastatic MIBC treatment guidelines, including a comprehensive treatment algorithm. He also discusses directions of future research for the disease.

Read More

Enhanced Techniques of Non-Muscle Invasive Bladder Cancer Detection

Michael S. Cookson, MD, describes the components of a quality transurethral resection of bladder tumor (TURBT), enhanced detection technologies such as blue light cystoscopy and narrow band imaging (NBI), and the induction of these new technologies into the American Urological Association (AUA) and Society of Urologic Oncology (SUO) bladder cancer guidelines and common practice.

Read More

Barriers to Clinical Trials for Non-Muscle Invasive Bladder Cancer

Ashish M. Kamat, MD, articulates the discrepancies in the American Urological Association and European Association of Urology bladder cancer treatment guidelines, challenges in defining a risk-stratification scale for the disease, knowledge gaps regarding BCG failure, and other factors that hinder the urological community’s ability to design quality clinical trials for non-muscle invasive bladder cancer.

Read More

Join the GRU Community

- Why Join? -